Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Pregnant women who take biologic medication for rheumatoid arthritis are not running the risk of their infant developing serious/opportunistic infections, according to research presented at the 2017 ...

If you have moderate to severe ulcerative colitis (UC) and haven’t found enough relief from traditional medications, your doctor may talk to you about biologics. These newer drugs, which include ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

Tumour necrosis factor (TNF) inhibitors are more likely discontinued due to ineffectiveness in patients aged 16-24 years than in those aged 45-54 years. However, patients aged ≥ 75 years have an ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

A major American medical device manufacturer is investing $110 million to expand production in Nebraska as part of an effort ...